View all veterinary jobs
VetSurgeon.org publishes a curated feed of veterinary news for practising veterinary surgeons, with a primary focus on the UK profession.
We select stories based on their practical relevance, clinical interest, or professional significance — filtering out noise so busy vets can stay informed quickly.
Our coverage includes:
We report across all areas of practice, including companion animal, farm, equine and exotic species.
Our editorial approach is deliberately selective and concise. We prioritise clarity and relevance over volume, aiming to make each story worth your time.
You can follow VetSurgeon News by subscribing to the daily, weekly or monthly email digest, or via our channels on Facebook and LinkedIn.
Cytopoint is an injectable monoclonal antibody therapy for dogs that targets and neutralises the cytokine IL-31, a mediator of allergic itch1.
Zoetis says the new claim was granted following a randomised, double-masked, multi-centred, placebo-controlled study which looked at Cytopoint’s efficacy and safety for the treatment of pruritus associated with allergic dermatitis in client-owned dogs. The study showed that Cytopoint significantly decreased pruritus, and improved skin lesions.2
Allison Henry, Product Manager Companion Animal Dermatology at Zoetis UK, says: "Allergic dermatitis is one of the most common skin conditions in dogs.3 The associated clinical signs – including scratching, hair loss and skin lesions – are disruptive for the dog, impacting their quality of life and that of its owner. Allergic skin disease is one of the most frequent reasons owners present their dog to a veterinarian.
"The licence extension demonstrates further innovation from Zoetis in the field of veterinary dermatology, and across the continuum of care, increasing the treatment options available to manage pruritus. Apoquel remains an ideal choice for short-term control due to its ability to provide rapid itch relief within four hours4 for as little as one day.5 This enables pruritus to be tightly controlled during the diagnostic work up,7 as well as being used for longer term control where tablets are the preferred method of administration.
"The sustained duration of action of Cytopoint makes it better suited to long-term management of pruritus, particularly when administering tablets is a challenge. Other benefits, such as no restrictions on age or with comorbidities, coupled with the flexibility of the new claim, make it a useful treatment at an earlier stage for more unique cases, e.g. young dogs or those with comorbidities."
For further information, contact your Zoetis Account Manager.
watch?v=A8EJ8LpLVzw&feature=youtu.be
References
Zoetis says that Cytopoint works by mimicking the activity of natural antibodies which selectively bind and neutralise canine interleukin-31 (cIL-31), a key cytokine involved in triggering itch in dogs.
The company says that because of the precision and specificity with which Cytopoint acts to target and neutralise cIL-31, it has been shown not to interfere with the immune response, meaning that it does not induce unintended immunosuppression or enhancement.
Dr. Emmanuel Bensignor, a specialist in veterinary dermatology in Paris, France, who participated in field studies conducted in Europe, said: "My personal experience with Cytopoint showed impressive speed of efficacy, significantly reducing itch in dogs from 24 hours onwards.
"Atopic dermatitis is a very common disease in dogs, and the owners I meet are desperate to find a rapid, reliable and safe solution for their suffering dogs. With its once monthly injection, I believe that Cytopoint has the potential to meet pet owners' needs for its convenience.
"European veterinary dermatologists and veterinarians will now have access to a new therapeutic class via this first monoclonal antibody treatment for veterinary use. It is a very exciting innovation which brings a notable improvement to the health and quality of life of the dogs and happiness to their families."
The recommended minimum efficacious dose for the treatment of clinical manifestations of atopic dermatitis in dogs is 1 mg/kg, which can be repeated monthly. Cytopoint will be available in single dose vials containing 10, 20, 30 or 40 mg/kg of lokivetmab.
For more information, visit the European Medicines Agency.
Fynadyne had been removed from sale last year after the Veterinary Medicines Directorate suspended the sale of any medicinal products containing the excipient diethanolamine (DEA), following advice to the European Medicines Agency that it could pose a risk to human health.
Finadyne 50mg/ml Solution for Injection is indicated for the alleviation of acute inflammation and pain in both cattle and pigs. It is also indicated for the alleviation of inflammation and pain associated with musculo-skeletal disorders and colic in horses.
The reformulated product has a shelf life of three years and is now available from wholesalers in 50ml and 100ml vials.
For further information, contact your MSD Animal Health account manager.
The research on which the new indication is based is described by Boehringer as the largest and most cutting-edge study in veterinary cardiology.
The EPIC study (Effect of Pimobendan in Dogs with asymptomatic MVD and Cardiomegaly)1 demonstrated that Vetmedin delayed the onset of heart failure for dogs with asymptomatic MVD, providing on average 15 months additional symptom-free time, as well as extending overall survival.
Indeed, Boehringer says the worldwide study was so conclusive - involving 360 dogs, in 36 centres, in 11 countries across four continents - that it was terminated early as it was deemed unethical to withhold Vetmedin from dogs in the placebo group.
Panny Morgan, Vetmedin brand manager at Boehringer Ingelheim, said: "Vetmedin delays the onset of heart failure in dogs with asymptomatic MVD and cardiomegaly, providing 15 months extra symptom-free time; that’s almost 10% of a dog’s lifetime.
"Prescribing Vetmedin to dogs with an MVD murmur and enlarged heart will not only extend a dog’s lifespan, but it will also have a major impact on their quality of life."
For further information on Vetmedin, contact your Boehringer Ingelheim territory manager or visit www.vetmedin.co.uk.
Reference
Paragon is being built by the Linnaeus Group, which says the new centre will be one of the largest and best-equipped in the UK when it opens its doors early in the New Year.
The new centre follows the Linnaeus Group's acquisition of Dewsbury-based Calder Vets last year.
Calder Vets' existing referral teams, together with two ophthalmologists from its Mirfield branch, will be transferring to Paragon. Meanwhile, Calder Vets will move to solely first-opinion work.
Currently nearing the end of construction, the centre will have eight consulting rooms, five operating theatres, MRI and CT scanners, intensive care facilities along with an all-digital imaging department.
A total of up to 80 staff will be employed at Paragon, including up to 18 referral vets and 32 veterinary nurses.
Specialist services will include cardiology, neurology, ophthalmology and orthopaedic and soft tissue surgery.
Positions currently available include a diagnostic imager, internal medicine specialist, neurology specialist, oncology specialist and an ophthalmologist, as well as various nursing posts.
Ian Monteith, managing director of Paragon, said: "We are looking for the best possible people who not only have the right skills and experience, but who will also fit into the ethos we want to create at Paragon.
"It is a significant and exciting opportunity for motivated, high calibre people to help shape something that has a very bright future for both the industry and for their own careers.
"Our philosophy is very much one of friendly cooperation between all members of staff, creating a pleasant, supportive and good-humoured atmosphere."
For details of the vacancies currently on offer at Paragon, visit www.paragonreferrals.co.uk/en-GB/careers
In the study titled 'Staphylococcal bacterial contamination of portable electronic devices in a large veterinary hospital1', samples were taken from the screen and any button of PEDs (such as mobile phones and tablets) of staff working directly with feline and canine patients. Hospital staff were asked to complete a questionnaire to ascertain the frequency of PED use and the frequency and method of PED cleaning.
The aim of the study was to determine the prevalence of Staphylococcal contamination of PEDs in a veterinary hospital, and to identify the source and determine the pathogenesis of any cultured strains.
Positive cultures were tested for resistance to oxacillin and vancomycin using a Kirby-Bauer disc diffusion test and then by using a broth microdilution test to EUCAST guidelines and breakpoints. PCR was used to specifically genotype the isolated staphylococci.
Georgia Vinall, corresponding author for the paper, said: “Useable swab samples were taken from 47 devices. Staphylococcus spp. were cultured from 68% of PEDs with a median of 10 colonies grown per device. Vancomycin-resistant Staphylococcus spp. were found on 36% of devices, whilst oxacillin-resistant Staphylococcus spp. were cultured from 2% of devices. DNA sequencing identified three Staphylococcus species; S. capitis, S. epidermidis and S. hominis which are most likely associated with humans as either sources or transmission vectors."
“The results of the survey indicate that 96% of staff had a PED which they used in the hospital environment, of which 85% use their device every day. Despite the high usage of PEDS in the hospital environment, only 6% of staff cleaned their device daily, with 33% of staff cleaning their PED less than weekly. Furthermore, only 54% of staff cleaned their device with a disinfectant."
Nicola Di Girolamo, Editor of JSAP said: "This study demonstrates that PEDs may become contaminated with potentially pathogenic microorganisms. Although this specific study did not focus on transmission of these microorganisms, and therefore it is unclear what are the clinical implications of this finding, it seems prudent to develop appropriate protocols for cleaning of PEDs in veterinary hospitals."
The full article can be found in the April issue of the Journal of Small Animal Practice and can be read online here: https://onlinelibrary.wiley.com/doi/10.1111/jsap.13289.
The company says Veterinary HPM Hypoallergy contains hydrolysed salmon protein for high digestive tolerance and optimal nutritional value, and no hidden proteins in its carbohydrate sources. Extensive hydrolysis is used to ensure hypoallergenic safety whilst maintaining palatability.
The company also claims the new diet has a higher level of animal protein and lower level of carbohydrate than other comparable products on the market for both cats and dogs, providing a clinical diet that is closest to their nutritional needs as carnivores.
Veterinary HPM Hypoallergy is designed to complement Veterinary HPM Dermatology Support, which is already available.
Tracey West, Nutrition Manager at Virbac said: "I am delighted to be able to introduce the much anticipated Veterinary HPM Hypoallergy to the Veterinary HPM Clinical Diets range.
"As pioneers in dermatology with more than 35 years of experience in this field, Virbac is proud to bring you, not 1 but 2, advanced nutritional solutions to help manage one of the most challenging clinical conditions faced in veterinary practice."
For more information, speak to your Virbac Territory Manager.
Participants travel around South Africa working on game reserves, commercial farms and in poor communities, getting experience of game capture, providing veterinary care in townships and rural areas, working in a private clinic and handling and treating large farm animals.
There are also a range of weekend activities, including kayaking, quad biking, game drives, horse riding, surfing, beach walking, bars and restaurants.
Kim said: “We’ve designed the programme so that it’s suitable for people with a wide range of experience, including veterinary and veterinary nursing students, young people considering a career in the veterinary profession and animal lovers.”
For more information, visit: wildinsideadventures.com
Danny Chambers MRCVS had a disappointing night after seeing the Liberal Democrat share of the vote in North Cornwall decrease by 5.8%, leaving him trailing 14,752 votes behind the Conservative candidate Scott Mann who scored 30,671.
Meanwhile Ian Fleming MRCVS, who stood as an independent candidate for the Halesowen and Rowley Regis constituency, got 190 votes. The winning Conservative candidate, James Morris, gained 25,607 votes.
Many people will no doubt feel that the overall Conservative majority of 80 seats is a disastrous result; people who simply cannot bear Boris and fear what he'll do with a majority; people who saw a land of milk and honey and free broadband and publicly-owned railways that run on time and an A&E waiting time of less than 30 seconds and guillotines for the rich, only to have their hopes dashed. They must be gutted.
Equally it can be argued that this is the best possible result for the country. A decisive vote. Now, finally, we can all move on from 3 years of interminable debate about whether we're staying or going or having another referendum or cancelling the whole thing and going down the pub instead. Now the government can concentrate on implementing brexit. Perhaps the country can at last unite around that purpose.
Boris may not prove the disaster that some people think. He's not hard right. Quite the reverse. And having won all those safe Labour seats, he'll have to deliver for them. He has a good sense of humour ("Let's get breakfast done."), but that does not make him a fool or a charlatan. On the contrary, wit requires brainpower. And as for the accusations of being a liar, perhaps people will come to understand that flowery use of language does not itself make someone dishonest. Perhaps people will learn to stop interpreting his words so literally.
Time will tell, but there is cause for optimism this morning. Whichever side of the fence you sit, we must all be glad of one thing ... no more arguing about whether or not we're leaving.
Ms Gatehouse faced two charges, the first being that she inaccurately assured another veterinary surgeon that she had vaccinated a horse against influenza and tetanus when she had not, and she subsequently failed to undertake adequate checks to confirm whether she had done so.
The second charge was that she later made a false entry in the same horse’s clinical records to cover up her previous inaccurate statement.
Ms Gatehouse admitted the facts alleged in relation to both charges and also admitted that in relation to the second charge she was guilty of disgraceful conduct in a professional respect.
The Committee, having heard submissions from Counsel for the RCVS and Ms Gatehouse found her guilty of disgraceful conduct in relation to the first charge.
Under the first charge the Committee found that she had breached the RCVS Code of Professional Conduct for Veterinary Surgeons by not keeping clear, accurate and detailed clinical and client records, and by acting in a manner that was likely to undermine public trust in the profession.
They also considered that her falsehood was unpremeditated, and that the decision was made in a moment of panic. Ultimately, however, by claiming the horse was vaccinated to another veterinary surgeon and not taking the necessary steps to confirm this, she failed to put the welfare of the animal first, potentially endangering it and any other horses it came into contact with, as well as potentially jeopardising the position of the veterinary surgeon she confirmed it to.
Having found Ms Gatehouse guilty of serious professional misconduct in relation to both parts of the charge the Committee then considered its sanction against her. In mitigation the Committee considered the fact that she had been in practice for 22 years without any untoward conduct, the testimony of three witnesses who attested to her being an honest and trustworthy practitioner, and the fact that Ms Gatehouse was in a troublesome relationship with the complainant until June 2014 which led her to be reluctant to contact him to correct her initial confirmation.
In summing up Stuart Drummond, Chair of the Committee, said: "The Committee has considers that it is material to have regard to the general emotional state to which the Respondent was reduced by the controlling and debilitating conduct of her then partner when they were living together and the consequential loss of self-esteem and ability to stand up to him and his demands. The deleterious effect of an abusive relationship lingers after such a relationship ends.
"Taking into account this knowledge, the Committee considers that the period of suspension that would, in other circumstances, be entirely merited, can properly be reduced in this instance to reflect the fact that this veterinary surgeon would not have acted as she did during this period but for the fact that her judgement was adversely affected by her experience at the hands of her then former partner.
"The decision is that, whilst it is necessary, in order sufficiently to protect animals and the wider public interest, to impose a period of suspension from practice, that period can be reduced to one of two months. In so concluding the Committee wishes to make it clear that this decision reflects the special features of this case."
Ms Gatehouse can choose to appeal the decision after a period of 28 days.
A Jack Russell from Thurso had a bit of a surprise last week, when it looked down the stethoscope to find Prince Charles at the other end.
The slightly unlikely encounter happened when the prince visited the newly-extended North Highland College Rural Studies Centre.
The purpose-built centre, which houses veterinary nursing, gamekeeping and equestrian students, boasts a nurse training area complete with theatre, prep room, isolation area and consultation room, where Prince Charles was invited to watch a bandaging demonstration and listen to the dog's heart murmur.
Over seventy guests attended the event and were introduced to Prince Charles before he was presented with a gift from vet nursing student Paula Morgan. Paula from Ayrshire, who is a former veterinary nursing student of the College said: "The facility is an absolutely fantastic asset to the College. It is so good for students having the equestrian studies section based just across the courtyard here too! It was a great honour to present Prince Charles with his gift at his visit to the newly revamped centre."
Alternative picture caption, anyone?
Dexafast is an injectable corticosteroid with potent, medium-acting, anti-inflammatory activity, indicated for the treatment of a range of inflammatory and allergic conditions in both small and large animal clinical practice.
Dr John Henderson, Large Animal Product Manager at Forte Healthcare Ltd said: "Dexafast 2mg/ml is an excellent addition to our range. This formulation of dexamethasone is used across many species on a daily basis, and Dexafast 2mg/ml gives vets a high-quality presentation of a staple medicine."
Dexafast is available in a 50ml bottle.
For further information, contact your local Forte Territory Manager, visit: https://www.fortehealthcare.ie/product/dexafast-uk-only, or email: enquiries@fortehealthcare.com.
Methadyne can be administered for analgesia of moderate to severe pain in dogs and cats, to provide neuroleptanalgesia in combination with a neuroleptic drug and as part of a patient’s premedication protocol prior to general anaesthesia.
The new presentation will now be available alongside the 10ml vial to give greater flexibility and to help reduce drug wastage and streamline controlled drug stock management.
Jurox says Methadyne has proven compatibility when combined in the same syringe with other aqueous solutions for injection containing acepromazine as maleate and medetomidine and dexmedetomidine as hydrochlorides.
Methadyne has a shelf life of 24 months unbroached, and 28 days broached. After broaching, the bung can be punctured to draw up a dose of methadone as many times as required in 28 days.
Dan Cripwell MRCVS, senior veterinary technical advisor at Jurox (UK) Limited, said: “I am delighted that Jurox can provide the UK veterinary market with this evolution in our multidose methadone formulation, which is now available in both 5ml and 10ml vials.
"We constantly strive to provide the veterinary profession with first class clinical and technical support and, in this instance, we were able to assess what improvements could be made to our existing drug portfolio and respond to the profession’s feedback to help reduce wastage of controlled drugs when they are needed in smaller volume."
For further information, contact your local Jurox account manager, phone 0800 500 3171, visit www.jurox.com/uk or email customerservice@jurox.co.uk.
Research shows that over 60% of cast-treated pets get additional injures, such as pressure sores, from traditional plaster casts1.
The new cast is designed to tackle these issues with anatomically shaped bi-valve splints that are based on 30,000 3D scans of animal limbs.
Upets TLC products are made from FDA and CE approved Woodcast material used in human casting and splinting.
Bandages, padding and tape are replaced with a soft, self-cohesive Unitex fabric that passes moisture and dries fast.
TLC products are engineered for easy destabilisation by removing parts of the splint, and the same product can be used throughout the whole treatment.
Orthopets, a subsidiary of the materials company Dassiet, says that breathable, lightweight materials combined with the anatomical fit help prevent sores and restore normal position and movement of the limb.
OrthoPets founder Martin Kaufmann said: “The common cast is very problematic, but we've lacked better alternatives. Now, with the Dassiet supermaterials and OrthoPets’ vast experience in veterinary biomechanics we have re-engineered the common cast.
"Upets TLC is anatomical and safe. It’s stress-free for both the vet and the pet. It brings veterinary casting to the modern day and offers a better standard care option for all vets and orthopaedic surgeons out there.”
"Sores, pain and stiffness are always on the horizon with casting. But if we take the cast off too early, the leg can be injured again because of lack of proper support. UPETS tackles these problems all at once. I find it easy to apply the pre-shaped casts even for very small or large dogs and make adjustments if needed. I can watch my patients walk off the clinic normally with their cast, knowing they can wear it safely until fully healed. We see significant and immediate improvement in patients compared to the common cast”, says Dassiet Chief Veterinarian Jouni Niemi, who oversees the clinical research of UPETS.
For more information, visit: www.upets.vet/TLC
The app, which was designed to provide veterinary surgeons, nurses and receptionists with quick access to up-to-date biological data on a wide range of exotic pets, now contains information about 40 different exotic pet species, from Grey Parrots to Sugar Gliders.
Each species entry offers an overview of the pet, details of common conditions, therapeutics and treatment videos.
Mark, pictured right with a Sulcata tortoise said: "There are a wide range of exotic pets that are becoming increasingly popular with pet owners, yet very few vets understandably have advanced knowledge in this niche area. The "Veterinary Care for Exotics" app for vets means vets, vet nurses and receptionists can now have this knowledge at their fingertips, giving them the reassuring back-up they need when presented with more unusual pets."
The app can be downloaded from Google Play and from Apple's app store, priced at £11.99.
For more information contact Mark Rowland: trinitycpd@gmail.com.
The company says Dormazolam works in synergy with other induction agents to provide an extended duration of anaesthesia without adversely affecting the quality of recovery 2,3,5.
Benzodiazepines are commonly incorporated into anaesthetic regimens to alleviate issues seen with the administration to ketamine alone2,3,4, including inadequate muscle relaxation2,3,4, anaesthesia not lasting long enough2 and induction failure2.
Despite the issues caused by the sole use of ketamine, it remains the primary anaesthetic induction agent of choice for more than 90% of equine vets2.
Dechra Brand Manager Emma Jennings said: “Using Dormazolam as part of an equine anaesthesia protocol will give optimal general anaesthetic conditions every time, including a rapid onset of action1.
"Anaesthetic co-induction with ketamine and midazolam has been shown to provide a superior quality of anaesthesia compared to ketamine alone3 and midazolam is equally as effective as diazepam when used as a co-induction agent alongside ketamine4. It also cuts down on the number of ketamine ‘top-up’ doses required compared to using ketamine3 alone.
"Additional benefits include no clinically significant differences in cardiopulmonary function1 or recovery times1 between midazolam and diazepam and it can be mixed in the same syringe as ketamine for ease of use4.”
Emma added: “The introduction of Dormazolam provides an exciting new option for equine vets. It delivers enhanced anaesthetic and surgical conditions by improving anaesthetic induction quality2,3,4 and giving better surgical relaxation scores2,3,4. It also reduces involuntary movements because, as a co-induction agent, midazolam only causes minimal cardiovascular and pulmonary depression2,4.”
Dormazolam is available in a 20 ml vial. It has a shelf life of four years and a broached shelf life of 28 days.
For more information, visit: www.dechra.co.uk/therapy-areas/equine/anaesthesia/analgesia.
References:
Developed by Zoetis, Apoquel is a prescription-only Janus kinase (JAK) inhibitor approved for veterinary use that targets the itch and inflammation pathway.
Ben Hurst, Product Manager, Zoetis UK said: "Atopic dermatitis is one of the most common allergies in dogs, affecting approximately 10% of the dog population1.
"Itching caused by an allergic skin disease can impact the quality of life for both the dog and its owner unless they are controlled with effective management.
"Apoquel chewable tablets now offer a new, convenient and palatable solution for dog owners."
Apoquel chewable tablets are administered twice daily for up to 14 days (at 0.4 to 0.6 mg/kg), then once daily for maintenance therapy.
Zoetis says marketing authorisation for the EU market is expected later this year following the Committee for Medicinal Products for Veterinary Use (CVMP) positive opinion received on 7th October 2021.
The practice, which is owned by the Linnaeus Group, says it will be refurbishing its existing facilities, extending its premises, hiring more specialist veterinary surgeons, veterinary nurses and support staff and installing state-of-the-art new equipment.
In addition, it plans to refresh its intern programme and launch a nurse training programme.
A six-month programme of building works will include a new reception area, consultation room and medicine and surgery wards.
New services and facilities will include a cat ward, X-ray department and endoscopy and chemotherapy facilities.
Operations manager Daniel Hogan (pictured right), said: "This is a very exciting period as we grow in every possible area and work more closely with referring practices to continue to develop our bespoke and exceptional service for patients and clients.
"Our aim is aspiring and simple: to create the very best referral centre possible by bringing together the expertise of the very best of veterinary professionals supported by the very latest in technological innovation."
For more information about Southfields Veterinary Specialists, visit: www.southfields.co.uk.
VetSurgeon members, husband and wife Cat Henstridge and Dave Hough MsRCVS have set up vCPD, a low cost CPD company based in the West Midlands.
Cat said: "Many of you will have noticed how CPD has become extremely expensive with some of the larger providers. Single days of theory based lectures are often well over £300+VAT, even for vet nurses, and more practical sessions can be far more than this. In these tough economic times it is a cost many practices can ill afford but one which, due to the RCVS regulations on Continuing Professional Development for both Vets and Vet Nurses, they are often forced to meet.
"vCPD is very different. Courses cost only £150 +VAT , all of which are given by highly qualified and experienced professionals (often the very same ones used by the more expensive companies) at an extremely convenient location, with excellent transport links and plenty of free parking, in the West Midlands. We are initially concentrating on vet nurses but will be expanding to vets later in the year."
You can find out more, view the courses and download a booking form by visiting http://www.vcpd.co.uk/. You can also follow vCPD on facebook and twitter.
Speed Reader can test for T4, Cortisol, CPSE, Progesterone and cCRP. Virbac highlights that it is the only in-clinic diagnostic biomarker test for CPSE, to screen dogs for Benign Prostatic Hyperplasia, of which 80% of intact male dogs over the age of 5 years old are at risk of developing (1,2).
Virbac says the Speed Reader gives practices an opportunity to increase in-clinic diagnostic testing, reduce their reliance on external laboratories, deliver immediate results and improve profitability.
Offered with an intuitive touch screen user interface and integrated printer, Speed Reader tests can be performed in as little as 15 minutes using a simple step-by-step procedure displayed on the touch screen.
Andrew Connolly, Head of Marketing – Companion Animals at Virbac said: "The Speed Reader biomarker range is a fantastic addition to Virbac’s diagnostic portfolio.
"Not only does Speed Reader offer practices improved in-clinic diagnostic testing, but having listened to customer feedback we are also offering Speed Reader with transparent, straightforward pricing and without complex commitment contracts."
Ziapam is licensed for the short-term control of convulsive disorders and muscle spasms of central and peripheral origin, and for use as part of a sedation or pre-anaesthetic protocol. It is presented in packs containing 6 x 2ml vials.
Simon Boulton MRCVS, marketing manager at TVM said: "As a scheduled intravenous drug it is important that we have batch traceability and the proper monitoring of any side effects of such drugs to make sure current guidelines for use in the SPC are correct. Ziapam is kept at the same concentration of the previously used human generics on the cascade for ease of transition."
Simon added: "Furthermore, we’ve purposefully priced Ziapam such that it is only costs a few pence per dose more than the human generic."
TVM UK has also produced a dosing guide for practices which illustrates the different indications and associated treatment guidelines.
For a copy of the dosing guide or for more information, contact your local Territory Manager, email: help@tvm-uk.com, or call: 01737 781 416.
In the week that Prince Charles has become embroiled in another row about the use of homeopathy in the NHS, British veterinary surgeons have denounced its use for the treatment of pets and other animals.
In a survey of veterinary surgeons carried out on this website, in which 460 members took part and the preliminary results of which are announced today, an overwhelming 83% said that there are no medical conditions for which homeopathy could be an effective treatment in animals. This figure included the 6.3% of participants who practice veterinary homeopathy themselves, without whom the figure would be even higher.
More specifically, when asked how they would best describe veterinary homeopathy, 4.5% said 'A reliably effective form of veterinary medicine', 8.7% said 'an occasionally effective form of veterinary medicine, 9.5% said: 'a rarely effective form of veterinary medicine, and 77.3% said: 'An ineffective form of veterinary medicine'.
The survey was carried with Alex Gough MA VetMB CertSAM CertVC PGCert MRCVS, Head of Medicine Referrals at Bath Veterinary Group.
So strongly did veterinary surgeons feel about the matter, 78.4% felt that their colleagues should not be allowed to practice homeopathy under their professional title of MRCVS. 73% said that whilst they are still allowed to do so, pet owners should be asked to sign a disclaimer that they understand that in trials, homeopathy has been shown to be ineffective.
However despite the almost universal denunciation of veterinary homeopathy within the profession, when it comes to directing their clients, it seems that many veterinary surgeons do not have quite the same courage of their convictions. Asked what would be the most appropriate response when asked by a client to refer an animal for homeopathic treatment, only 24% of vets said they would explain that homeopathy does not work and recommend the client does not self-refer for homeopathic treatment. 17.5% said they would explain that homeopathy does not work and advise the client to self-refer. 34% said that they would explain that homeopathy doesn't work and refer anyway, and 24% said they would just refer the case.
The newspaper report said things have been so bad at the school that 20 staff left following conflicts with Professor Argyle and an investigation by the University and College Union (UCU) found "shocking levels of harassment".
Furthermore, an agency hired by the university to investigate the claims broadly supported the UCU's findings.
Nevertheless, a University of Edinburgh spokesperson told VetSurgeon.org that: "An internal review has fully and robustly investigated these claims of bullying and found no evidence of misconduct. The decision was upheld after an appeal."
"We have also held discussions with UCU, and have well-developed plans for staff development at the Easter Bush campus and for a survey of all staff who work there"
A UCU spokesperson added: “UCU raised the very serious concerns on a culture of bullying and harassment at the university’s veterinary school with the employer last year, and has been working together with senior management to address these issues. We will be discussing the next steps with management and we will consult with our members to gauge their views on the plans to improve working conditions”.
For the full report, visit (paywall): https://www.thetimes.co.uk/article/top-vet-professor-david-argyle-at-centre-of-bullying-claims-at-edinburgh-university-5hlnmwjl8
The Australian company, which launched in the UK offering equine specials in March 2017, says that while some human healthcare companies are authorised to supply veterinary specials under licence in the UK, it is currently the only company in the UK to have specific veterinary authorisation to manufacture sterile specials.
There are six formulations in Bova’s new small animal range with a further 23 formulations scheduled to be introduced in the first half of 2018. However, Bova says that due to advertising restrictions, only verified veterinary surgeons will be able to see its formulation list.
For more information, contact Bova Sales Manager Emma Jones on tel: 07780443731 or Victoria Dawson on 07780443738 or visit www.bova.co.uk.
The company will also be at BSAVA Congress this week on stand 817, where they will be offering the chance to win an afternoon champagne tea at the Ritz.
Virbac has launched the UK's first blood test for BPH (benign prostatic hyperplasia) which, according to the company, will provide practices with a significant opportunity to improve the prognosis for many of the UK's male dog population that suffer from the condition but go undetected.
Odelis CPSE is the first ELISA test to screen, diagnose and monitor BPH. Virbac Product Manager Chris Geddes MRCVS believes that the test is an important step forward in the diagnosis of the condition: "Not only does Odelis CPSE provide a simple and reliable alternative to rectal palpation, it will also give an objective measure of the degree of BPH present."
According to Chris, although BPH affects over 80% of entire male dogs over five years old, many go undiagnosed until the condition is advanced and symptoms become apparent. "Whilst regular screening is recommended in elderly dogs, rectal palpation is not a particularly popular process to carry out routinely without the presence of symptoms.
"We know that currently diagnosis of BPH falls well below the incidence, however this new test means that practitioners can now routinely monitor 'at-risk' dogs, e.g. stud males, elderly dogs, and those with a previous history of BPH. Bloods can be taken at practice visits, or routinely at vaccination boosters or annual health checks for example. So the test is not only good for animal welfare, it's a great business opportunity too".
There are three labs in the UK selected to carry out the test: Biobest; Carmichael Torrance; and Nationwide Laboratories.
Information is being mailed to all practices. Your first test free, and all positive test results recorded up to 31st October will receive a 'buy one get one free' promotion for Ypozane (osaterone acetate), the first-line treatment for BPH.
Alternatively, contact your local Virbac territory manager, or call Virbac on 01359 243243.